English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The article presents the results of a clinical study, the aim of which was to evaluate the efficacy and safety of chemotherapy regimens based on nitrosoureas derivative aranose used in 1-5 line therapy for metastatic neuroendocrine tumors (mNET) of different localization. Patients (n = 49) included in the study received one of three regimens: monotherapy with aranose (480-690 mg/m2 intravenously on 1 st -3 rd days every 3 weeks), aranose in combination with capecitabine (aranose 500 -760 mg / m2 intravenously 1 st -2 nd days; capecitabine 2g / m2 / day 1 st -14 th days every 3 weeks) and aranose in combination with temozolomide (aranose, 450 mg / m2 intravenously 1 st -2 nd days; temozolomide 100 mg / m2 / day 3 rd -6 th days every 3 weeks). Monotherapy with aranose received 20 patients, aranose/ capecitabine combination - 22 patients, and aranose / temozolomide combination - 7 patients. A total of 337 courses of chemotherapy were conducted. According to the assessment of the effectiveness of aranose, aranose/capecitabine, aranose/temozolomide regimens objective response rate was 40%; 22.7%; 28.6%, respectively, and the control the tumor growth was 75%; 77.3%; 57.2% respectively. All these regimens were well tolerated. The most frequent adverse event was 1-2 grade of hematologic toxicity. Thus, aranose in monotherapy and in combination with other cytostatics showed anti-tumor activity and characterized with satisfactory tolerability.

Chemotherapy of metastatic neuroendocrine tumors with aranose in monoregimen and in combination with capecitabine and temozolomide.